Schizophrenia Clinical Trials in Oceanside, California

6 studies are recruiting for schizophrenia in Oceanside, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

   ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Clinical Site, Oceanside, California

   Locations

   42 in total

   Run by

   MapLight Therapeutics

   See if you can join NCT07459647 on ClinicalTrials.gov

2. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

   This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   Excell Research Inc, Oceanside, California

   Locations

   64 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT06229210 on ClinicalTrials.gov

3. Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

   The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

   Stage

   Not phased

   Ages

   18 and older

   Site

   Local Institution - 0043, Oceanside, California

   Locations

   55 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07379827 on ClinicalTrials.gov

4. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

   This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Neurocrine Clinical Site, Oceanside, California

   Locations

   57 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07114874 on ClinicalTrials.gov

5. Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

   The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Neurocrine Clinical Site, Oceanside, California

   Locations

   20 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07227818 on ClinicalTrials.gov

6. Randomized Withdrawal Study in Patients With Schizophrenia

   The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Vanda Investigational Site, Oceanside, California

   Locations

   22 in total

   Run by

   Vanda Pharmaceuticals

   See if you can join NCT06961968 on ClinicalTrials.gov